Sophia Genetics Sa Stock Earnings Reports

SOPHiA GENETICS delivered a strong Q1 2026: revenue grew 22% year-over-year to $21.7M, platform analyses set a company record at ~108,000 (including a March monthly record >40,000), and adjusted gross margin remained high at 75.4%, demonstrating platform scalability. Core clinical customers rose to 537 and net dollar retention improved to 117%, driven by cross-sell (new higher‑value applications such as liquid biopsy/MSK Access and enhanced exomes). MSK Access has reached ~100 customers worldwide and liquid biopsy volumes are ramping (3,000 analyses in Q1, +100% YoY). Biopharma momentum increased with new contracts (e.g., AstraZeneca, J&J), while management is building a global CDx and real-world-evidence offering. Management took modest cost actions (mostly G&A/support) and is deploying internal AI tools to drive efficiency. Key headwinds include FX translation from a stronger Swiss franc, ongoing patent litigation with Guardant (Q1 legal expense partially offset by interim cost awards), and soft performance in Latin America. Cash and equivalents were $65.4M at quarter end (including $14.5M ATM proceeds) and an expanded $25M credit facility. The company reaffirmed full‑year 2026 guidance: revenue $92–94M (≈20–22% growth) and adjusted EBITDA loss $29–32M, while aiming to approach adjusted EBITDA breakeven by end of 2026 and reach positive adjusted EBITDA in H2 2027. Risks to the outlook include litigation outcomes, FX volatility, and regional market softness.